OIS@ASCRS
Bausch + Lomb, a Valeant Pharmaceuticals company, remains the only firm with an FDA-approved accommodating IOL, the Crystalens AO. Andrew Chang, general manager and senior…
Read More
Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG, shares how his company’s long history in ophthalmology helps it pave a path for…
Read More
Ophthalmology veteran Tom Frinzi joins OISTV to share his reasons for joining Abbott Medical Optics and what the company may be planning in coming years.…
Read More
The termination of the Pfizer-Allergan merger actually left some in ophthalmology feeling relief. We ask Bill Meury of Allergan how did Allergan employees feel about…
Read More
Ashley McEvoy, Company Chair of Vision Care and Diabetes at Johnson & Johnson, joins OISTV to discuss Johnson & Johnson’s commitment to eye health. Video…
Read More
Calvin Roberts, MD, CMO at Bausch & Lomb lends his physician’s perspective to how companies like Bausch & Lomb can serve eye care. Video Highlights…
Read More
In a packed ballroom at the Intercontinental Hotel, OIS attendees recognized the achievements of one of ophthalmology’s physician-innovators. Roger F. Steinert, MD, was honored as…
Read More
The KAMRA small-aperture corneal inlay from AcuFocus was approved by the FDA in April 2015 for the treatment of presbyopia, and the company began a…
Read More
Ocular Therapeutix expects to hear from the FDA on its PDUFA date of July 24, 2016, on its new drug application for DEXTENZA, its sustained-release…
Read More
Heidelberg Engineering, which has more than 10,000 optical coherence tomography (OCT) units in place worldwide, is looking to help drive the premium channel by entering…
Read More
Phase II results of ForSight Vision5’s bimatoprost ocular ring insert have shown the ring achieves clinically significant reductions in intraocular pressure (IOP) over six months…
Read More
A panel of physicians and corporate leaders discuss the increasingly important impact diagnostics have on the premium channel. Topics included number of tests done, appetite…
Read More
SUBSCRIBE TO OIS NEWS
Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.
We respect your privacy and promise to never send you spam.
![OIS-ANTERIOR-NEW-DATE-750x420[4300]](https://ois.net/wp-content/uploads/2020/03/OIS-ANTERIOR-NEW-DATE-750x4204300.jpg "OIS-ANTERIOR-NEW-DATE-750x420[4300]")